Media Coverage

Twenty-three New Jersey companies have been recognized as a “Best Place to Work for LGBTQ Equality” by the Human Rights Campaign Foundation, the educational arm of the country’s largest lesbian, gay, bisexual and transgender civil rights organization.[CR-LF][CR-LF]According to the 2020 Corporate Equality Index, more than 680 companies were assessed and designated with the honor for their efforts in satisfying four criteria ⁠— non-discrimination policies, employment benefits, corporate social responsibility and responsible citizenship ⁠—earning them a score of 100%. Quest is included in this list.

Quest Diagnostics today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2020 for the sixth consecutive year.

From makeup and oils to capsules for stress relief, cannabis-based goods are flowing into the marketplace. But while they may not get you high, they can still cause you problems at work. Cannabidiol or CBD has been showing up in a widening array of goods. That's because federal legislation in 2018 deemed that hemp - one of its sources - was not an illegal controlled substance.

Employers must provide a safe work environment, and they want to ensure their employees are productive, but is maintaining a drug-testing program in furtherance of these goals worth the hassle? The answer may depend on the workplace.[CR-LF][CR-LF]"You have to consider the needs of the business, in addition to any applicable state laws," said Anne-Marie Welch, an attorney with Clark Hill in Birmingham, Mich. Some employers are federal contractors or hire drivers and have to follow specific drug-free workplace laws. Other employers are struggling to find qualified employees or want to maintain a certain culture and think that drug testing—particularly for marijuana—will hinder their ability to attract and retain talent.

LabCorp and Quest went into 2019 predicting some upsides to the Protecting Access to Medicare Act​ (PAMA), which is driving down how much Medicare pays for tests. The clinical laboratory leaders objected to the price cuts but felt they were better equipped to cope with them than smaller rivals, creating opportunities to consolidate the market.[CR-LF][CR-LF]However, the anticipated surge in acquisitions of local and hospital laboratories never materialized. Adam Schechter, who took over as CEO of LabCorp in November, discussed some reasons for lack of M&A activity during a presentation at the J.P. Morgan Healthcare Conference Tuesday.